417 related articles for article (PubMed ID: 18042006)
1. An update on the pharmacology of galantamine.
Villarroya M; García AG; Marco-Contelles J; López MG
Expert Opin Investig Drugs; 2007 Dec; 16(12):1987-98. PubMed ID: 18042006
[TBL] [Abstract][Full Text] [Related]
2. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
[TBL] [Abstract][Full Text] [Related]
3. Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease.
Lilienfeld S
CNS Drug Rev; 2002; 8(2):159-76. PubMed ID: 12177686
[TBL] [Abstract][Full Text] [Related]
4. [Nicotinic Receptor, galantamine and Alzheimer disease].
Arroyo G; Aldea M; Fuentealba J; García AG
Rev Neurol; 2002 Jun 1-15; 34(11):1057-65. PubMed ID: 12134305
[TBL] [Abstract][Full Text] [Related]
5. A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer's Disease.
Korabecny J; Spilovska K; Mezeiova E; Benek O; Juza R; Kaping D; Soukup O
Curr Med Chem; 2019; 26(30):5625-5648. PubMed ID: 29768996
[TBL] [Abstract][Full Text] [Related]
6. The pharmacological rationale for treating vascular dementia with galantamine (Reminyl).
Maelicke A
Int J Clin Pract Suppl; 2001 May; (120):24-8. PubMed ID: 11406923
[TBL] [Abstract][Full Text] [Related]
7. Nicotinic cholinergic modulation: galantamine as a prototype.
Woodruff-Pak DS; Lander C; Geerts H
CNS Drug Rev; 2002; 8(4):405-26. PubMed ID: 12481195
[TBL] [Abstract][Full Text] [Related]
8. Update on Alzheimer drugs (galantamine).
Raskind MA
Neurologist; 2003 Sep; 9(5):235-40. PubMed ID: 12971834
[TBL] [Abstract][Full Text] [Related]
9. [Development of therapies for Alzheimer's disease based on cholinergic hypothesis-status quo and future directions].
Shimohama S
Rinsho Shinkeigaku; 2013; 53(11):1036-8. PubMed ID: 24291871
[TBL] [Abstract][Full Text] [Related]
10. Galantamine in Alzheimer's disease.
Razay G; Wilcock GK
Expert Rev Neurother; 2008 Jan; 8(1):9-17. PubMed ID: 18088197
[TBL] [Abstract][Full Text] [Related]
11. A molecular approach in drug development for Alzheimer's disease.
Agatonovic-Kustrin S; Kettle C; Morton DW
Biomed Pharmacother; 2018 Oct; 106():553-565. PubMed ID: 29990843
[TBL] [Abstract][Full Text] [Related]
12. Switching cholinesterase inhibitors in patients with Alzheimer's disease.
Emre M
Int J Clin Pract Suppl; 2002 Jun; (127):64-72. PubMed ID: 12139369
[TBL] [Abstract][Full Text] [Related]
13. Current status and new developments with galantamine in the treatment of Alzheimer's disease.
Tariot P
Expert Opin Pharmacother; 2001 Dec; 2(12):2027-49. PubMed ID: 11825333
[TBL] [Abstract][Full Text] [Related]
14. A review on cholinesterase inhibitors for Alzheimer's disease.
Anand P; Singh B
Arch Pharm Res; 2013 Apr; 36(4):375-99. PubMed ID: 23435942
[TBL] [Abstract][Full Text] [Related]
15. [Acetylcholinesterase inhibitors for dementia--an update].
Anghelescu I; Heuser I
MMW Fortschr Med; 2007 May; 149 Suppl 2():76-8. PubMed ID: 17724973
[TBL] [Abstract][Full Text] [Related]
16. [Galantamine: a novel cholinergic agent for Alzheimer's disease].
Olazarán J; García G
Neurologia; 2002 Oct; 17(8):429-36. PubMed ID: 12396973
[TBL] [Abstract][Full Text] [Related]
17. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2001; (1):CD001747. PubMed ID: 11279727
[TBL] [Abstract][Full Text] [Related]
18. [Galantamine].
Taéron C
Rev Infirm; 2008 Sep; (143):44-6. PubMed ID: 18788671
[No Abstract] [Full Text] [Related]
19. Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer's disease.
Kim SH; Kandiah N; Hsu JL; Suthisisang C; Udommongkol C; Dash A
Br J Pharmacol; 2017 Dec; 174(23):4224-4232. PubMed ID: 28901528
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease.
Geerts H; Grossberg GT
J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):8S-16S. PubMed ID: 16809810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
